Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

NCT07084610 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant)

Sponsor

Hospital das Clínicas de Ribeirão Preto